September 7, 2006 – King Pharma paid $265 million to buy Avinza, an extended release morphine drug, from Ligand Pharma; Dynavax will collaborate with AstraZeneca to develop therapies for asthma and COPD; Martek dropped after reducing its outlook for the rest of the fiscal year; GTx out-licensed the European rights for Acapodene, a cancer drug, to Ipsen; Abbott Labs filed for approval of Humira as a therapy for Crohn’s disease; GlaxoSmithKline released positive data from three studies of orlistat, a weight-loss drug; Myogen began a Phase III trial of ambrisentan as a treatment for pulmonary hypertension; and Amylin reported positive data from a study that added Symlin to basal insulin glargine. The Centient Biotech 200™ fell 22 points to 3694.99, a loss of .59%. More data...
